RxDoctor Payments Data

Alyson Adams

Family · Lancaster, OHNPI 1477820462

Payments from drug & device makers

$2,205in general payments, 2019–2025

Across 121 payments — averaging $18.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$526
  • Johnson & Johnson$331
  • Amgen$279
  • Pfizer$278
  • AstraZeneca$264
  • Novo Nordisk$177
  • plus $349 from 9 others

What the payments were for

  • Food & beverage$1,97690%
  • Education$22910%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,205 in reported general payments places this provider in the 80th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$59,142
Medicare patients
447
Services billed
637

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban646$526,150
XareltoRivaroxaban221$187,265
EntrestoSacubitril/Valsartan70$75,685
Repatha SureclickEvolocumab57$65,824
JardianceEmpagliflozin20$15,281
BrilintaTicagrelor15$14,961
Metoprolol Succinate751$11,189
Praluent PenAlirocumab21$10,590
Ranolazine ErRanolazine75$10,461
Atorvastatin Calcium499$5,425
Isosorbide Mononitrate ErIsosorbide Mononitrate239$3,653
Carvedilol437$3,073
Potassium Chloride197$2,896
ClopidogrelClopidogrel Bisulfate282$2,606
Nebivolol Hcl34$2,322

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$278$526,150646 claims
Johnson & JohnsonXarelto$331$187,265221 claims
NovartisEntresto$526$75,68570 claims
Boehringer IngelheimJardiance$19$15,28120 claims
AstraZenecaBrilinta$264$14,96115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,812 family providers in Ohio.

Other family in Lancaster

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →